clinical Study on Skin Eruptions

Clinical Validation of a Unani Pharmacopoeial formulation Arq-e-Chiraita in Buthur-i-Jild (Skin Eruptions) - CSBJ

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2023/03/050704

Enrollment

120

Registered

2023-03-15

Start date

Unknown

Completion date

Unknown

Last updated

2023-04-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L988- Other specified disorders of the skin and subcutaneous tissue

Interventions

Intervention1: Arq Chiraita: the dosage of Arq Chiraita is 125 ml. its frequency is twice daily for 30 days . the route of administration is oral. Control Intervention1: no comparator: no comparator

Eligibility

Inclusion criteria

Inclusion criteria: Participants may have any of the following symptoms Itching Burning sensation Oozing Participants may have any of the following skin lesions: Maculo- papules Papules Pustules Vesicles

Exclusion criteria

Exclusion criteria: Immuno-compromised clinical conditions such as diabetes mellitus, cancer, HIV/AIDS,etc Known cases of other clinically significant co-morbid conditions (severe hepatic, renal, cardiovascular disorders, etc.) Known hypersensitivity to study drug or any of its ingredients Pregnant and Lactating Women

Design outcomes

Primary

Measure	Time frame
To assess the safety of a Unani Pharmacopoeial formulation Arqâ??e-Chiraita in Buthur-i- Jild To assess the efficacy of a Unani Pharmacopoeial formulation Arq-e-Chiraita in Buthur-i- Jild. Timepoint: 30 days	—

Secondary

Measure	Time frame
nilTimepoint: nil	—

Countries

India

Contacts

Public ContactMohammad Nawab

National Research Institute of Unani Medicine for Skin Disorders

ccrumnawab@gmail.com8100992044

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026